Alvotech (ALVO) fair value analysis
Nasdaq · Updated 2026-10-19
ALVO price how computed
Valuation status
Awaiting full valuationALVO's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once ALVO's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $5.00
- Sector
- Healthcare
- 12-month range
- $3.00–$8.40
- Market cap
- $1.78B
- From 52-week high
- -40.5%
- Shares outstanding
- 357M
- Rank in Healthcare by quality score
- #117 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Alvotech is a pharmaceutical company that develops and manufactures biosimilar medications, which are biologic drugs designed to replicate the effects of existing approved biological therapies. The company operates internationally with a focus on bringing biosimilar treatments to patients in various markets around the world.
ALVO currently ranks #117 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.78B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $492M
- Net margin
- -36.5%
- EPS (TTM)
- $-0.30
- Gross margin
- 50.7%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 164.9%
- Shares outstanding
- 357M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $5.14
- 200-day average
- $4.21
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-83.3%)
2026-03 ▼ miss (-28.6%)
2025-12 ▲ beat (+112.0%)
2025-09 ▼ miss (-266.7%)
2025-06 ▲ beat (+1404.3%)
2025-03 ▲ beat (+1066.7%)
2024-12 ▼ miss (-700.0%)
2024-09 ▼ miss (-700.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 1 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $6.8
- Target vs last price
- +36.0%
What our data shows for ALVO
- Our model validated 1 trailing price-to-earnings windows for ALVO, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $3.00–$8.40.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ALVO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ALVO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ALVO's 50/200-day trend state shifted from uptrend to mixed during this week, indicating a change in the stock's intermediate momentum dynamics. The company operates in the Healthcare sector and currently carries a valuation verdict of awaiting full valuation according to TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — ALVO's Relative Strength Index moved from the overbought zone to the neutral zone this week, indicating a shift in the stock's momentum dynamics. The Healthcare sector company's valuation assessment remains under review as complete valuation data is being compiled.
- 2026-09-21 — ALVO's 50/200-day trend state shifted from mixed to uptrend this week, reflecting a change in the underlying derived indicators tracked by TickrTrends. The stock operates within the Healthcare sector and currently maintains an awaiting full valuation verdict. This technical transition suggests a strengthening of shorter-term momentum relative to longer-term price direction.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ALVO stock undervalued?
ALVO's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is ALVO's TickrTrends verdict?
ALVO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once ALVO's own trailing P/E history validates under our standards.
How does ALVO compare to other Healthcare stocks?
ALVO ranks #117 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ALVO overbought or oversold?
ALVO's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ALVO report earnings next?
ALVO's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does ALVO usually beat earnings estimates?
Over its last 8 reported quarters ALVO beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALVO?
Of 7 analysts covering ALVO, 6 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $6.8 (+36.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.